Crossmark

Plasma cell-free DNA methylation profile before afatinib treatment is associated with progression-free and overall survival of patients with epidermal growth factor receptor gene mutation-positive non-small cell lung cancer

Crossref DOI link: https://doi.org/10.1186/s13148-025-01870-8

Published Online: 2025-04-25

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fujimoto, Mao

Yasuda, Hiroyuki

Arai, Eri https://orcid.org/0000-0002-0076-4823
Nakajima, Makoto

Takata, Saori

Morikawa, Kei

Tanaka, Hisashi

Itani, Hidetoshi

Honda, Takeshi

Horiuchi, Kazuya

Watanabe, Kageaki

Nakagawa, Hideyuki

Nakahara, Yoshiro

Seki, Yoshitaka

Bessho, Akihiro

Takahashi, Nobumasa

Hayashi, Kentaro

Endo, Takeo

Takeyama, Kiyoshi

Maekura, Toshiya

Takigawa, Nagio

Kawase, Akikazu

Endoh, Makoto

Nemoto, Kenji

Kishi, Kazuma

Soejima, Kenzo

Okuma, Yusuke

Togashi, Akira

Matsutani, Noriyuki

Seki, Nobuhiko

Kanai, Yae https://orcid.org/0000-0002-7904-9506
Funding

Funding for this research was provided by:

Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan (S01PA84234, S01PA84234)
License Information

Text and Data Mining valid from 2025-04-25

Version of Record valid from 2025-04-25
More Information

Article History

Received: 21 January 2025

Accepted: 31 March 2025

First Online: 25 April 2025

Declarations

:

: This study complied with the Declaration of Helsinki and was approved by the Ethics Committee at Keio University School of Medicine (2021–0147) and the Ethical Review Board for Medical and Health Research Involving Human Subjects at Teikyo University (16–066). All participants provided written informed consent.

: AT is an employee of Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan.

Document is current

Any future updates will be listed below